INKT News and Press, MiNK Therapeutics Inc. From 10/30/23

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune...

2023-08-23 05:36:55 ET Summary MiNK Therapeutics is developing "off the shelf" allogeneic cell therapies for cancer using iNKT cells. Their first iNKT cell therapy, agenT-797, showed a pro-inflammatory cytokine response and some efficacy in patients with solid tumors. The comp...

-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center -  iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress -  MiNK-2...

Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, ...

75% survival in patients with severe respiratory distress treated with agenT-797 agenT-797 improved lung function, significantly reduced inflammation and secondary infections MiNK to advance agenT-797 in ARDS through externally financed programs NEW YORK, May 22, 2023 (GLOBE NEWSW...

FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling studies underway; IND filing on track for 2024 NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-st...

2023-05-14 14:25:03 ET MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Ch...

agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists without lymphodepletion. Initiating phase 1/2 expansion studies in NSCLC and gastric cancer, with majority costs planned for external, non-di...